Güven Barış, Deniz Muhammed Furkan, Geylan Neziha Aybüke, Kültürsay Barkın, Dönmez Ayça, Bulat Zübeyir, Gül Ömer Burak, Kaya Melike, Oktay Veysel
Department of Cardiology, Idil State Hospital, Sirnak, Turkey.
Department of Cardiology, Sirnak State Hospital, Sirnak, Turkey.
Biomark Med. 2025 Apr;19(8):287-294. doi: 10.1080/17520363.2025.2483159. Epub 2025 Mar 24.
This study aimed to identify the prognostic significance of the C-reactive protein-albumin-lymphocyte (CALLY) index for predicting all-cause mortality in acute coronary syndrome (ACS) patients who have undergone primary percutaneous coronary intervention (pPCI) for revascularization.
505 patients who presented with ACS and underwent pPCI were retrospectively included in this single center study. CALLY index and other five prognostic scores were calculated. The median follow-up was 40 months. All-cause mortality was defined as the primary endpoint.
The median age of the patients was 59 years, 23.4% were female. The CALLY index was categorized into low (<0.7) and high (≥0.7). Age ( = 0.038), concomitant atrial fibrillation ( = 0.023), previous CABG ( = 0.001), ACE-I/ARB/ARNI use ( = 0.015), diuretic use ( = 0.021), and a low-CALLY index ( < 0.001) were identified as independent predictors of all-cause mortality in multivariate cox regression analysis. When compared to other prognostic scores according to AUC in ROC analysis, the CALLY index demonstrated the best ability to predict all-cause mortality. Additionally, patients with a high-CALLY index exhibited significantly better survival outcomes compared to those with a low-CALLY index (log-rank: < 0.001).
CALLY index can be utilized as a novel prognostic score for predicting all-cause mortality in ACS patients who have undergone pPCI.
本研究旨在确定C反应蛋白-白蛋白-淋巴细胞（CALLY）指数对接受直接经皮冠状动脉介入治疗（pPCI）进行血运重建的急性冠状动脉综合征（ACS）患者全因死亡率的预测价值。
本单中心研究回顾性纳入了505例表现为ACS并接受pPCI的患者。计算CALLY指数和其他五个预后评分。中位随访时间为40个月。全因死亡率被定义为主要终点。
患者的中位年龄为59岁，女性占23.4%。CALLY指数分为低（<0.7）和高（≥0.7）两组。在多因素Cox回归分析中，年龄（=0.038）、合并心房颤动（=0.023）、既往冠状动脉旁路移植术（CABG）（=0.001）、使用血管紧张素转换酶抑制剂（ACE-I）/血管紧张素受体阻滞剂（ARB）/血管紧张素受体脑啡肽酶抑制剂（ARNI）（=0.015）、使用利尿剂（=0.021）以及低CALLY指数（<0.001）被确定为全因死亡率的独立预测因素。在ROC分析中，与其他预后评分相比，CALLY指数预测全因死亡率的能力最佳。此外，与低CALLY指数的患者相比，高CALLY指数的患者生存结局显著更好（对数秩检验：<0.001）。
CALLY指数可作为预测接受pPCI的ACS患者全因死亡率的一种新的预后评分。
